Home  »  Finance   »  Rubius Therapeutics Inc. (RUBY): Don’t disre...

Rubius Therapeutics Inc. (RUBY): Don’t disregard this ominous signal

Rubius Therapeutics Inc. (RUBY) is priced at $0.25 after the most recent trading session. At the very opening of the session, the stock price was $0.2293 and reached a high price of $0.25, prior to closing the session it reached the value of $0.23. The stock touched a low price of $0.22.Recently in News on November 2, 2022, Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes. Dannielle Appelhans to Become President and Chief Executive Officer. You can read further details here

Rubius Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $0.3103 on 01/13/23, with the lowest value was $0.1500 for the same time period, recorded on 01/06/23.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Rubius Therapeutics Inc. (RUBY) full year performance was -96.75%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Rubius Therapeutics Inc. shares are logging -96.83% during the 52-week period from high price, and 78.50% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.14 and $7.88.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 580087 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Rubius Therapeutics Inc. (RUBY) recorded performance in the market was 42.80%, having the revenues showcasing -29.86% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 22.90M, as it employees total of 9 workers.

Rubius Therapeutics Inc. (RUBY) in the eye of market guru’s

During the last month, 0 analysts gave the Rubius Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.3642, with a change in the price was noted -0.43. In a similar fashion, Rubius Therapeutics Inc. posted a movement of -63.36% for the period of last 100 days, recording 2,951,091 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for RUBY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.10.

Rubius Therapeutics Inc. (RUBY): Stocks Technical analysis and Trends

Raw Stochastic average of Rubius Therapeutics Inc. in the period of last 50 days is set at 39.25%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.25%. In the last 20 days, the company’s Stochastic %K was 34.15% and its Stochastic %D was recorded 33.91%.

If we look into the earlier routines of Rubius Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 42.80%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -67.60%, alongside a downfall of -96.75% for the period of the last 12 months. The shares increased approximately by -15.20% in the 7-day charts and went down by 73.18% in the period of the last 30 days. Common stock shares were lifted by -29.86% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts